Shares dropped after the biotech reported what seemed like good news. What's going on?
News & Analysis: Nabriva Therapeutics
Paratek Corp., Nabriva Therapeutics, and Cempra all appear on course to bring new antibiotics to market soon. But which could be the best bet for your portfolio now?
The roller-coaster ride continues for this clinical-stage biotech's stock.
Analyst upgrades and news that the company's balance sheet is getting a makeover caused traders to cheer.
Shares soar after the company reports upbeat data from a pivotal clinical trial.